Indivior Pharmaceuticals, Inc. issued a press release on October 29, 2026, reporting its financial results for the third quarter ended September 30, 2026. The company reported total net revenue of $356 million for the quarter, representing a 13% increase year-over-year. Total SUBLOCADE net revenue reached $267 million, up 22% compared to the prior year.
Indivior achieved record quarterly net income of $137 million and record non-GAAP net income of $161 million for the third quarter of 2026. The company also reported record quarterly Adjusted EBITDA of $211 million, which is a 76% increase year-over-year. The net income margin was 39%, and the Adjusted EBITDA margin was 59% for the quarter.
As of September 30, 2026, over 583,000 patients in the U.S. have been prescribed SUBLOCADE since its launch. The company noted that U.S. SUBLOCADE net revenue increased 24% year-over-year to $252 million, driven by a 17% increase in dispense unit volume and more favorable price/mix adjustments.
Regarding its pending merger with Supernus Pharmaceuticals, Inc., Indivior stated it is on track to close the transaction on November 2, 2026. Upon closing, the combined company will operate as Supernus, Inc. and trade on the Nasdaq Global Select Market under the ticker symbol “SUPN” beginning November 3, 2026.
Indivior also announced that its Board of Directors declared a special cash dividend contingent upon the closing of the merger. The company reported cash and investments of $332 million at the end of the third quarter.
Looking ahead, Indivior stated it is on track to achieve its previously communicated full-year 2026 guidance as a standalone organization prior to the merger closing. The guidance for the full year includes total net revenue between $1.295 billion and $1.365 billion, total SUBLOCADE net revenue between $1.010 billion and $1.050 billion, and Adjusted EBITDA between $700 million and $740 million.
